Societal CDMO (SCTL) 10-Q 9 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 07, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Trading Symbol	REPH
Entity Registrant Name	Recro Pharma, Inc.
Entity Central Index Key	1,588,972
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		19,123,935

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 11,803,000	$ 64,483,000
Short-term investments	29,507,000
Accounts receivable	13,126,000	10,411,000
Inventory	9,891,000	8,746,000
Prepaid expenses and other current assets	2,785,000	1,118,000
Total current assets	67,112,000	84,758,000
Property, plant and equipment, net	38,197,000	37,300,000
Deferred income taxes	21,759,000	17,060,000
Intangible assets, net	35,496,000	37,433,000
Goodwill	6,446,000	6,446,000
Total assets	169,010,000	182,997,000
Current liabilities:
Accounts payable	2,823,000	4,132,000
Accrued expenses and other current liabilities	9,150,000	9,893,000
Current portion of contingent consideration	30,372,000
Current portion of long-term debt, net	0	2,236,000
Total current liabilities	42,345,000	16,261,000
Long-term debt, net	24,890,000	22,152,000
Warrants and other long-term liabilities	3,600,000	3,397,000
Long-term portion of contingent consideration	48,525,000	69,574,000
Total liabilities	119,360,000	111,384,000
Commitments and contingencies (Note 13)
Shareholders’ equity:
Preferred stock, $0.01 par value. Authorized, 10,000,000 shares; none issued and outstanding
Common stock, $0.01 par value. Authorized, 50,000,000 shares; issued and outstanding, 19,060,260 shares at September 30, 2017 and 19,043,216 shares at December 31, 2016	191,000	190,000
Additional paid-in capital	136,732,000	132,691,000
Accumulated deficit	(87,265,000)	(61,268,000)
Accumulated other comprehensive loss	(8,000)
Total shareholders’ equity	49,650,000	71,613,000
Total liabilities and shareholders’ equity	$ 169,010,000	$ 182,997,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	19,060,260	19,043,216
Common stock, shares outstanding	19,060,260	19,043,216

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
Revenue	$ 17,114	$ 16,951	$ 52,790	$ 51,973
Operating expenses:
Cost of sales (excluding amortization of intangible assets)	6,882	5,745	27,829	25,563
Research and development	9,296	7,046	24,132	23,175
General and administrative	6,635	3,841	16,990	9,263
Amortization of intangible assets	646	646	1,937	1,937
Change in warrant valuation	808	402	15	47
Change in contingent consideration valuation	3,550	3,192	9,323	7,705
Total operating expenses	27,817	20,872	80,226	67,690
Operating loss	(10,703)	(3,921)	(27,436)	(15,717)
Other income (expense):
Interest income	62	10	284	27
Interest expense	(1,235)	(1,450)	(3,625)	(4,279)
Net loss before income taxes	(11,876)	(5,361)	(30,777)	(19,969)
Income tax benefit (expense)	2,821	(18)	4,780	166
Net loss	$ (9,055)	$ (5,379)	$ (25,997)	$ (19,803)
Per share information:
Net loss per share of common stock, basic and diluted	$ (0.48)	$ (0.50)	$ (1.36)	$ (2.01)
Weighted average common shares outstanding, basic and diluted	19,058,956	10,780,911	19,053,636	9,862,526
Other comprehensive loss:
Unrealized gain (loss) on available-for-sale securities	$ 68		$ (8)
Comprehensive loss	$ (8,987)	$ (5,379)	$ (26,005)	$ (19,803)

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity (Unaudited) - 9 months ended Sep. 30, 2017 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Balance at Dec. 31, 2016	$ 71,613	$ 190	$ 132,691	$ (61,268)
Balance, Shares at Dec. 31, 2016		19,043,216
Stock-based compensation expense	4,265		4,265
Stock option exercise	$ 27	$ 1	26
Stock option exercise, Shares	4,256	4,256
Issuance of restricted stock units	$ (250)		(250)
Issuance of restricted stock units, Shares		12,788
Other comprehensive loss	(8)				$ (8)
Net loss	(25,997)			(25,997)
Balance at Sep. 30, 2017	$ 49,650	$ 191	$ 136,732	$ (87,265)	$ (8)
Balance, Shares at Sep. 30, 2017		19,060,260

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net loss	$ (25,997)	$ (19,803)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	4,265	2,799
Non-cash interest expense	612	800
Depreciation expense	3,655	3,756
Amortization of intangible assets	1,937	1,937
Acquired in-process research and development charges	766
Change in warrant valuation	15	47
Change in contingent consideration valuation	9,323	7,705
Deferred income taxes	(4,698)	(352)
Changes in operating assets and liabilities, net of effect of acquisition:
Inventory	(1,146)	(830)
Prepaid expenses and other current assets	(1,667)	(911)
Accounts receivable	(2,715)	(3,844)
Accounts payable, accrued expenses and other liabilities	(2,391)	4,498
Net cash used in operating activities	(18,041)	(4,198)
Cash flows from investing activities:
Purchase of property and equipment	(4,586)	(2,014)
Purchase of short-term investments	(55,626)
Proceeds from maturity/redemption of investments	26,000
Acquisition of license agreement	(437)
Net cash used in investing activities	(34,649)	(2,014)
Cash flows from financing activities:
Proceeds from Aspire facility		4,175
Payments on long-term debt		(6,324)
Proceeds from sale of common stock, net of transaction costs		13,367
Payments of withholdings on shares withheld for income taxes	(17)	(33)
Proceeds from option exercise	27
Net cash provided by financing activities	10	11,185
Net decrease in cash and cash equivalents	(52,680)	4,973
Cash and cash equivalents, beginning of period	64,483	19,779
Cash and cash equivalents, end of period	11,803	24,752
Supplemental disclosure of cash flow information:
Cash paid for interest	3,122	3,479
Cash paid for taxes	467
Unrealized loss on available-for-sale securities	8
Purchase of property, plant and equipment included in accrued expenses and accounts payable	774	307
Amortization of deferred equity costs		$ 224
Withholdings on shares withheld for income taxes included in accrued expenses	233
Retirement of fully depreciated property, plant and equipment	$ 152

Background

Background	9 Months Ended
	Sep. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Background	(1) Background Recro Pharma, Inc., or the Company, was incorporated in Pennsylvania on November 15, 2007. The Company is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating contract development and manufacturing, or CDMO division. Each of these divisions are deemed to be reportable segments (see Note 3(m) and Note 17). The Acute Care division is primarily focused on developing innovative products for hospital and other acute care settings, and the CDMO division leverages the Company’s formulation expertise to develop and manufacture pharmaceutical products using the Company’s proprietary delivery technologies for commercial partners who commercialize or plan to commercialize these products. On April 10, 2015, the Company acquired from Alkermes plc, or Alkermes, worldwide rights to intravenous and intramuscular, or injectable, meloxicam, a proprietary long-acting preferential COX-2 inhibitor being developed for the management of moderate to severe pain, as well as a contract manufacturing facility, royalty and formulation business in Gainesville, Georgia. The acquisition is referred to herein as the Gainesville Transaction. In July 2017, the Company submitted a New Drug Application, or NDA, to the U.S. Food and Drug Administration, or the FDA, for its lead investigational product candidate intravenous, or IV, meloxicam 30 mg for the management of moderate to severe pain. The FDA has accepted the NDA for review and has set a Prescription Drug User Fee Act, or PDUFA, date of May 26, 2018.

Development-Stage Risks and Liq

Development-Stage Risks and Liquidity	9 Months Ended
	Sep. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Development-Stage Risks and Liquidity	(2) Development-Stage Risks and Liquidity The Company has incurred losses from operations since inception and has an accumulated deficit of $87,265 as of September 30, 2017. Though its CDMO segment has been profitable, the Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its products currently in development. Additional financing will be needed by the Company to fund its operations and to commercially develop its product candidates, including the payment of the Gainesville Transaction contingent payments, which may become due upon achievement of certain development and commercialization milestones for meloxicam (see Note 4). Insufficient funds may cause the Company to delay, reduce the scope of or eliminate one or more of its development, commercialization or expansion activities. The Company may raise such funds through debt refinancing, bank or other loans, through strategic research and development, licensing (including out-licensing) and/or marketing arrangements or through public or private sales of equity or debt securities from time to time. Financing may not be available on acceptable terms, or at all, and failure to raise capital when needed could materially adversely impact the Company’s growth plans and its financial condition or results of operations. Additional equity financing, if available, may be dilutive to the holders of its common stock and may involve significant cash payment obligations and covenants that restrict the Company’s ability to operate its business. The Company’s future operations are highly dependent on a combination of factors, including (i) the continued profitability of the CDMO segment; (ii) the timely and successful completion of additional financing and/or alternative sources of capital, debt, partnering or out-licensing transactions; (iii) the success of its research and development, including the results and timing of its clinical trials; (iv) the development of competitive therapies by other biotechnology and pharmaceutical companies; and, ultimately, (v) regulatory approval and market acceptance of the Company’s proposed future products. Management believes that the Company’s existing cash, cash equivalents and short-term investments as of September 30, 2017 will be sufficient to fund its operations through mid-year 2018.

Summary of Significant Accounti

Summary of Significant Accounting Principles	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Principles	(3) Summary of Significant Accounting Principles (a) Basis of Presentation and Principles of Consolidation The accompanying unaudited consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, for interim financial information and with the instructions of Form 10-Q and Article 10 of Regulation S-X and, therefore, do not include all of the information and notes required by the U.S. GAAP for complete annual financial statements. The Company’s consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. In the opinion of management, the accompanying consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s results for the interim periods. Operating results for the three and nine months ended September 30, 2017 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2017. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December 31, 2016 included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016. (b) Use of Estimates The preparation of financial statements and the notes to the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. (c) Cash and Cash Equivalents Cash and cash equivalents represents cash in banks and highly liquid short-term investments that have maturities of three months or less when acquired to be cash equivalents. These highly liquid short-term investments are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of the changes in interest rates. (d) Property and Equipment Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets, which are as follows: three to ten years for furniture and office equipment; six to ten or more years for manufacturing equipment; two to five years for vehicles; 35 to 40 years for buildings; and the shorter of the lease term or useful life for leasehold improvements. Repairs and maintenance cost are expensed as incurred. (e) Business Combinations In accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 805, “Business Combinations,” or ASC 805, the Company allocates the purchase price of acquired companies to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. Valuations are performed to assist in determining the fair values of assets acquired and liabilities assumed, which requires management to make significant estimates and assumptions, in particular with respect to intangible assets. Management makes estimates of fair value based upon assumptions believed to be reasonable. These estimates are based in part on historical experience and information obtained from management of the acquired companies and expectations of future cash flows. Transaction costs and restructuring costs associated with the transaction are expensed as incurred. In-process research and development, or IPR&D, is the value assigned to those projects for which the related products have not received regulatory approval and have no alternative future use. Determining the portion of the purchase price allocated to IPR&D requires the Company to make significant estimates. In a business combination, the Company capitalizes IPR&D as an intangible asset, and for an asset acquisition the Company expenses IPR&D in the Consolidated Statements of Operations and Comprehensive Loss on the acquisition date. (f) Goodwill and Intangible Assets Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill is not amortized, but assessed for impairment on an annual basis or more frequently if impairment indicators exist. The impairment model prescribes a two-step method for determining impairment. The first step compares a reporting unit’s fair value to its carrying amount to identify potential goodwill impairment. If the carrying amount of a reporting unit exceeds the reporting unit’s fair value, the second step of the impairment test must be completed to measure the amount of the reporting unit’s goodwill impairment loss, if any. Step two requires an assignment of the reporting unit’s fair value to the reporting unit’s assets and liabilities to determine the implied fair value of the reporting unit’s goodwill. The implied fair value of the reporting unit’s goodwill is then compared with the carrying amount of the reporting unit’s goodwill to determine the goodwill impairment loss to be recognized, if any. Intangible assets include the Company’s royalties and contract manufacturing relationships intangible asset as well as an IPR&D asset. The royalties and contract manufacturing relationships intangible asset is considered a definite-lived intangible asset and is amortized on a straight-line basis over a useful life of six years. Intangible assets related to IPR&D are considered indefinite-lived intangible assets and are assessed for impairment annually or more frequently if impairment indicators exist. If the associated research and development effort is abandoned, the related assets will be written-off, and the Company will record a noncash impairment loss on its Consolidated Statements of Operations and Comprehensive Loss. For those compounds that reach commercialization, the IPR&D assets will be amortized over their estimated useful lives. The impairment test for indefinite-lived intangible assets is a one-step test, which compares the fair value of the intangible asset to its carrying value. If the carrying value exceeds its fair value, an impairment loss is recognized in an amount equal to the excess. Based on accounting standards, it is required that these assets be assessed at least annually for impairment unless a triggering event occurs between annual assessments, which would then require an assessment in the period which a triggering event occurred. The most recent tests as of November 30, 2016, indicated that goodwill and indefinite-lived intangible assets were not impaired. There were no indicators of impairment as of September 30, 2017. (g) Revenue Recognition The Company generates revenues from research and development, manufacturing, packaging and related services for multiple pharmaceutical companies through its CDMO segment. The agreements that the Company has with its commercial partners provide for manufacturing revenues, royalties and/or profit sharing components. Manufacturing and other related services revenue is recognized when persuasive evidence of an arrangement exists, shipment has occurred and the title to the product and associated risk of loss has passed to the customer, the sales price is fixed or determinable and collectability is reasonably assured. In addition to manufacturing and packaging revenue, the customer agreements have royalties and/or profit sharing payments, computed on the net product sales of the commercial partner. Royalty and profit sharing revenues are generally recognized under the terms of the applicable license, development and/or supply agreement in the period the products are sold and when collectability is reasonably assured. Revenues related to research and development are generally recognized as the related services or activities are performed, in accordance with the contract terms. To the extent that the agreements specify services are to be performed on a fixed basis, revenues are recognized consistent with the pattern of the work performed. In agreements which specify milestones, the Company recognizes revenue from non-refundable milestone payments when the earnings process is complete and the payment is reasonably assured. Non-refundable milestone payments related to arrangements under which the Company has continuing performance obligations would be deferred and recognized over the period of performance. (h) Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. The Company manages its cash, cash equivalents and short-term investments based on established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company’s accounts receivable balances are concentrated amongst approximately five customers and if any of these customers’ receivable balances should be deemed uncollectible, it could have a material adverse effect on the Company’s results of operations and financial condition. (i) Research and Development Research and development costs for the Company’s proprietary products/product candidates are charged to expense as incurred. Research and development expenses consist primarily of funds paid to third parties for the provision of services for pre-commercialization and manufacturing scale-up activities, drug development, clinical trials, statistical analysis and report writing and regulatory filing fees and compliance costs. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expenses relating to these costs. Upfront and milestone payments made to third parties who perform research and development services on the Company’s behalf are expensed as services are rendered. Costs incurred in obtaining product technology licenses are charged to research and development expense as acquired IPR&D if the technology licensed has not reached technological feasibility and has no alternative future use. (j) Stock-Based Awards The Company measures employee stock-based awards at grant-date fair value and recognizes employee compensation expense on a straight-line basis over the vesting period of the award. Determining the appropriate fair value of stock options requires the input of subjective assumptions, including the expected life of the option and expected stock price volatility. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and/or management uses different assumptions, stock-based compensation expense could be materially different for future awards. The expected life of stock options was estimated using the “simplified method,” as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. For stock price volatility, the Company uses the historical volatility of our publicly traded stock in order to estimate future stock price trends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. Non-employee stock-based awards are revalued until an award vests and the Company recognizes compensation expense on a straight-line basis over the vesting period of each separated vesting tranche of the award, which is known as the accelerated attribution method. The estimation of the number of stock awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from the Company’s current estimates, such amounts are recognized as an adjustment in the period in which estimates are revised. (k) Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized. Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the consolidated financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company does not anticipate significant changes in the amount of unrecognized income tax benefits over the next year. (l) Net Loss Per Common Share Basic net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted average common shares outstanding during the period. For all periods presented, the outstanding common stock options, warrants and unvested restricted stock units have been excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. For purposes of calculating diluted loss per common share, the denominator includes both the weighted average common shares outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. There are no dilutive common stock equivalents for the three and nine months ended September 30, 2017 The following table sets forth the computation of basic earnings per share and diluted earnings per share: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Basic Earnings Per Share Net loss $ (9,055 ) $ (5,379 ) $ (25,997 ) $ (19,803 ) Weighted average common shares outstanding, basic and diluted 19,058,956 10,780,911 19,053,636 9,862,526 Net loss per share of common stock, basic and diluted $ (0.48 ) $ (0.50 ) $ (1.36 ) $ (2.01 ) The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of September 30, 2017 and 2016, as they would be anti-dilutive: September 30, 2017 2016 Options and restricted stock units outstanding 3,928,013 2,363,794 Warrants 784,928 784,928 Amounts in the table above reflect the common stock equivalents of the noted instruments. (m) Segment Information The Company determined its reportable segments based on its strategic business units, the commonalities among the products and services within each segment and the manner in which the Company reviews and evaluates operating performance. The Company has identified CDMO and Acute Care as reportable segments. Segment disclosures are included in Note 17. Segment operating profit (loss) is defined as segment revenue less segment operating expenses (segment operating expenses consist of general and administrative expenses, research and development expenses, and the change in valuation of contingent consideration and warrants). The following items are excluded from segment operating profit (loss): interest income and expense, and income tax benefit (expense). Segment assets are those assets and liabilities that are recorded and reported by segment operations. Segment operating capital employed represents segment assets less segment liabilities. (n) Recent Accounting Pronouncements In July 2017, the FASB issued Accounting Standards Update, or ASU, No. 2017-11 “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): Accounting for Certain Financial Instruments with Down Round Features,” In May 2017, the FASB issued ASU No. 2017-09, Stock Compensation - Scope of Modification Accounting In January 2017, the FASB issued ASU No. 2017-04 “Intangibles - Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment,” In August 2016, the FASB issued ASU No. 2016-15 “Classification of Certain Cash Receipts and Cash Payments,” In February 2016, the FASB issued ASU No. 2016-02, “ Leases (Topic 842), In September 2015, the FASB issued ASU No. 2015-16, “ Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments,” ASU 2015-16 addresses In July 2015, the FASB issued ASU No. 2015-11, “ Simplifying the Measurement of Inventory,” In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers,”

Acquisition of Gainesville Faci

Acquisition of Gainesville Facility and Meloxicam	9 Months Ended
	Sep. 30, 2017
Gainesville [Member]
Acquisition of Gainesville Facility and Meloxicam	(4) Acquisition of Gainesville Facility and Meloxicam On April 10, 2015, the Company completed the Gainesville Transaction. The consideration paid in connection with the Gainesville Transaction consisted of $50.0 million cash at closing, a $4.0 million working capital adjustment and a seven-year warrant to purchase 350,000 shares of the Company’s common stock at an exercise price of $19.46 per share. In addition, the Company may be required to pay up to an additional $125.0 million in milestone payments including $45 million upon regulatory approval, as well as net sales milestones related to injectable meloxicam and a percentage of future product net sales related to injectable meloxicam between 10% and 12% (subject to a 30% reduction when no longer covered by patent). Under the acquisition method of accounting, the consideration paid and the fair value of the contingent consideration and royalties are allocated to the fair value of the assets acquired and liabilities assumed. The contingent consideration obligation is remeasured each reporting date with changes in fair value recognized as a period charge within the statement of operations (see Note 6 for further information regarding fair value). The contingent consideration consists of three separate components. The first component will be payable upon regulatory approval. The second component consists of three potential payments, based on the achievement of specified annual revenue targets. The third component consists of a royalty payment for a defined term on future meloxicam net sales. The fair value of the first contingent consideration component recognized on the acquisition date was estimated by applying a risk-adjusted discount rate to the probability-adjusted contingent payments and the expected approval dates. The fair value of the second contingent consideration component recognized on the acquisition date was estimated by applying a risk-adjusted discount rate to the potential payments resulting from probability-weighted revenue projections and expected revenue target attainment dates. The fair value of the third contingent consideration component recognized on the acquisition date was estimated by applying a risk-adjusted discount rate to the potential payments resulting from probability-weighted revenue projections and the defined royalty percentage. These fair values are based on significant inputs not observable in the market, which are referred to in the guidance as Level 3 inputs. The contingent consideration components are classified as liabilities and are subject to the recognition of subsequent changes in fair value through the results of operations.

NMB Related License Agreement

NMB Related License Agreement	9 Months Ended
	Sep. 30, 2017
Business Combinations [Abstract]
NMB Related License Agreement	(5) NMB Related License Agreement In June 2017, the Company acquired the exclusive global rights to two novel neuromuscular blocking agents, or NMBs, and a proprietary chemical reversal agent from Cornell University, or Cornell. The NMBs and reversal agent are referred to herein as the NMB Related Compounds. The NMB Related Compounds include one novel intermediate-acting NMB that has initiated Phase I clinical trials and two other agents, a novel short-acting NMB, and a rapid-acting reversal agent proprietary to these NMB Related Compounds. The transaction was accounted for as an asset acquisition, with the total cost of the acquisition of $766 allocated to acquired IPR&D. The Company recorded an upfront payment obligation of $350, as well as operational liabilities and acquisition-related costs of $416, primarily consisting of reimbursement to Cornell for specified past patent, legal and pre-clinical costs, of which $329 is reported as a component of Accrued expenses and other current liabilities and Other non-current liabilities on the Consolidated Balance Sheet as of September 30, 2017. In addition, the Company is obligated to make: (i) an annual license maintenance fee payment until the first commercial sale of the NMB Related Compounds; and (ii) milestone payments upon the achievement of certain milestones, up to a maximum, for each NMB, of $5 million for U.S. regulatory approval and commercialization milestones and $3 million for European regulatory approval and commercialization milestones. The Company is also obligated to pay Cornell royalties on net sales of the NMB Related Compounds at a rate ranging from low to mid-single digits, depending on the applicable NMB Related Compounds and whether there is a valid patent claim in the applicable country, subject to an annual minimum royalty amount. Further, the Company will reimburse Cornell ongoing patent costs related to prosecution and maintenance of the patents related to the Cornell patents for the NMB Related Compounds. The Company accounted for the transaction as an asset acquisition based on an evaluation of the accounting guidance (ASC Topic 805) and considered the early clinical stage of the novel and unproven NMB Related Compounds. The Company concluded that the acquired IPR&D of Cornell did not constitute a business as defined under ASC 805 due to the incomplete nature of the inputs and the absence of processes from a market participant perspective. Substantial additional research and development will be required to develop any NMB Related Compounds into a commercially viable drug candidate, including completion of pre-clinical testing and clinical trials, and, if such clinical trials are successful, application for regulatory approvals and manufacturing repeatability and scale-up. There is risk that a marketable compound may not be well tolerated and may never be approved. Acquired IPR&D in the asset acquisition was accounted for in accordance with FASB ASC Topic 730, “Research and Development.” At the date of acquisition, the Company determined that the development of the projects underway at Cornell had not yet reached technological feasibility and that the research in process had no alternative future uses. Accordingly, the acquired IPR&D was charged to expense in the Consolidated Statements of Operations and Comprehensive Loss on the acquisition date. The acquired IPR&D charge is expected to be deductible over a 15-year period for income tax purposes.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	(6) Fair Value of Financial Instruments The Company follows the provisions of FASB ASC Topic 820, “Fair Value Measurements and Disclosures,” for fair value measurement recognition and disclosure purposes for its financial assets and financial liabilities that are remeasured and reported at fair value each reporting period. The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, short-term investments, warrants and the contingent consideration. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of financial assets and financial liabilities and their placement within the fair value hierarchy. Categorization is based on a three-tier valuation hierarchy, which prioritizes the inputs used in measuring fair value, as follows: • Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities; • Level 2: Inputs that are other than quoted prices in active markets for identical assets and liabilities, inputs that are quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are either directly or indirectly observable; and • Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company has classified assets and liabilities measured at fair value on a recurring basis as follows: Fair value measurements at reporting date using Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) At December 31, 2016: Assets: Money market mutual funds (See Note 7) $ 37,079 $ — $ — U.S. Treasury obligations (See Note 7) 20,517 — — Cash equivalents $ 57,596 $ — $ — Liabilities: Warrants (See Note 14(d)) — — $ 3,397 Contingent consideration (See Note 4) — — 69,574 $ — $ — $ 72,971 At September 30, 2017: Assets: Cash equivalents Money market mutual funds (See Note 7) $ 134 $ — $ — Total cash equivalents $ 134 $ — $ — Short-term investments U.S. Treasury obligations (See Note 7) $ 29,507 $ — $ — Total financial assets $ 29,641 $ — $ — Liabilities: Warrants (See Note 14(d)) — — $ 3,412 Contingent consideration (See Note 4) — — 78,897 $ — $ — $ 82,309 The Company developed its own assumptions to determine the value of the warrants that do not have observable inputs or available market data to support the fair value. This method of valuation involves using inputs such as the fair value of the Company’s common stock, stock price volatility, the contractual term of the warrants, risk free interest rates and dividend yield. Due to the nature of these inputs, the valuation of the warrants is considered a Level 3 measurement. The reconciliation of the contingent consideration and warrants measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows: Warrants Contingent Consideration Balance at December 31, 2016 $ 3,397 $ 69,574 Additions — — Remeasurement 15 9,323 Total at September 30, 2017 $ 3,412 $ 78,897 Current portion — 30,372 Long-term portion 3,412 48,525 The current portion of the contingent consideration represents the estimated probability adjusted fair value that is expected to become payable within one year as of September 30, 2017 (see Note 4 for additional information). The Company follows the disclosure provisions of FASB ASC Topic 825, “Financial Instruments” (ASC 825), for disclosure purposes for financial assets and financial liabilities that are not measured at fair value. As of September 30, 2017, the financial assets and liabilities recorded on the Consolidated Balance Sheets that are not measured at fair value on a recurring basis include accounts receivable, accounts payable, accrued expenses and current debt obligations approximate fair value due to the short-term nature of these instruments. The fair value of long-term debt, where a quoted market price is not available, is evaluated based on, among other factors, interest rates currently available to the Company for debt with similar terms, remaining payments and considerations of the Company’s creditworthiness. The Company determined that the recorded book value of long-term debt approximated fair value at September 30, 2017 due to the estimated amount of the Excess Cash Flow payments and terms of the debt.

Short-term Investments

Short-term Investments	9 Months Ended
	Sep. 30, 2017
Investments Debt And Equity Securities [Abstract]
Short-term Investments	(7) Short-term Investments Short-term investments as of September 30, 2017 consist of government money market funds and U.S. Treasury obligations. In accordance with FASB ASC Topic 320, “Investments – Debt and Equity Securities,” or ASC 320, the Company has classified its entire investment portfolio as available-for-sale securities with secondary or resale markets, and, as such, its portfolio is reported at fair value with unrealized gains and losses included in Comprehensive Income in stockholders’ equity and realized gains and losses included in other income/expense. The following is a summary of available-for-sale securities as of September 30, 2017. September 30, 2017 Amortized Gross Unrealized Estimated Description Cost Gain Loss Fair Value Money market mutual funds $ 134 $ — $ — $ 134 U.S. Treasury obligations 29,515 — (8 ) 29,507 Total investments $ 29,649 $ — $ (8 ) $ 29,641 As of September 30, 2017, the Company’s investments had maturities ranging from one to four months. As of December 31, 2016, all of the Company’s investments in US. Treasury obligations had original maturities of less than three months. The fair value of the Company’s U.S. Treasury obligations is determined by taking into consideration valuations obtained from third-party pricing services. The third-party pricing services utilize industry standard valuation models, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, and other observable inputs. Certain investment securities as of September 30, 2017 had fair values less than their amortized costs and, therefore, contained unrealized losses. The Company has evaluated these investments and has determined that the decline in value was not related to any Company or industry specific event. As of September 30, 2017, there were 15 U.S. Treasury investments with unrealized losses. The gross unrealized losses related to these investments were due to changes in interest rates. Given that the Company has no intent to sell any of these investments until a recovery of its fair value, which may be at maturity, and there are no current requirements to sell any of these investments, the Company did not consider these investments to be other-than-temporarily impaired as of September 30, 2017. The Company anticipates full recovery of amortized costs with respect to these investments at maturity or sooner in the event of a more favorable market interest rate environment. The duration of time the investments had been in a continuous unrealized loss position as of September 30, 2017 was less than 6 months.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2017
Inventory Disclosure [Abstract]
Inventory	(8) Inventory Inventory is stated at the lower of cost and net realizable value. Included in inventory are raw materials and work-in-process used in the production of commercial products. Cost is determined using the first-in, first-out method. Inventory was as follows as of September 30, 2017 and December 31, 2016: September 30, 2017 December 31, 2016 Raw materials $ 2,584 $ 2,618 Work in process 4,472 5,219 Finished goods 3,529 1,793 10,585 9,630 Provision for inventory obsolescence (694 ) (884 ) $ 9,891 $ 8,746 The provision for inventory obsolescence decreased approximately $190 during the nine months ended September 30, 2017, primarily due to the disposal of the fully reserved inventory at December 31, 2016. Adjustments to inventory are determined at the raw materials, work-in-process, and finished good levels to reflect obsolescence or impaired balances. Inventory is ordered to meet specific customer orders and largely reflects demand. Factors influencing inventory obsolescence include changes in demand, product life cycle, product pricing, physical deterioration and quality concerns.

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2017
Property Plant And Equipment [Abstract]
Property, Plant and Equipment	(9) Property, Plant and Equipment Property, plant and equipment consists of the following: September 30, 2017 December 31, 2016 Land $ 3,263 $ 3,263 Building and improvements 15,744 15,613 Furniture, office and computer equipment 4,993 3,811 Vehicles 30 30 Manufacturing equipment 22,602 21,508 Construction in progress 4,191 2,198 50,823 46,423 Less: accumulated depreciation and amortization 12,626 9,123 Property, plant and equipment, net $ 38,197 $ 37,300 Depreciation expense for the three and nine months ended September 30, 2017 was $1,231 and $3,655, respectively. Depreciation expense for the three and nine months ended September 30, 2016 was $1,245 and $3,756, respectively.

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets	(10) Intangible Assets The following represents the balance of the intangible assets at September 30, 2017: Cost Accumulated Amortization Net Intangible Assets Royalties and contract manufacturing relationships: $ 15,500 $ 6,404 $ 9,096 In-process research and development 26,400 — 26,400 Total $ 41,900 $ 6,404 $ 35,496 The following represents the balance of intangible assets at December 31, 2016: Cost Accumulated Amortization Net Intangible Assets Royalties and contract manufacturing relationships: $ 15,500 $ 4,467 $ 11,033 In-process research and development 26,400 — 26,400 Total $ 41,900 $ 4,467 $ 37,433 Amortization expense for each of the nine months ended September 30, 2017 and 2016 was $1,937 and $1,937, respectively, and for the three months ended September 30, 2017 and 2016 was $646. As of September 30, 2017, future amortization expense is as follows: Amortization October - December 2017 $ 645 2018 2,583 2019 2,583 2020 2,583 2021 702 Total $ 9,096

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2017
Payables And Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	(11) Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following: September 30, December 31, 2017 2016 Clinical trial and related costs $ — $ 2,564 Professional and consulting fees 551 360 Payroll and related costs 4,996 4,547 Property plant and equipment 495 720 Deferred revenue 563 418 Income tax payable — 311 Other 2,545 973 $ 9,150 $ 9,893

Long-Term Debt

Long-Term Debt	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Long-Term Debt	(12) Long-Term Debt The Company financed the Gainesville Transaction with cash on hand and a $50,000 five-year senior secured term loan, pursuant to a credit agreement, entered into on April 10, 2015, with OrbiMed Royalty Opportunities II, LP, or OrbiMed. The unpaid principal amount under the credit agreement is due and payable on April 10, 2020, the five-year anniversary of the loan provided thereunder by OrbiMed. The credit agreement also provides for certain mandatory prepayment events, including a quarterly excess cash flow prepayment requirement at OrbiMed’s request. The Company may make voluntary prepayments in whole or in part, subject to: (i) on or prior to the 36-month anniversary of the closing of the credit agreement, payment of a buy-out premium amount equal to (A) for full prepayments of the unpaid principal amount, $75,000 less all previously prepaid principal amounts and all previously paid interest or (B) for partial prepayments of the unpaid principal amount, 0.5 times the partial prepayment amount less interest payments previously paid in respect to the partial prepayment amount and (ii) after the 36-month anniversary of the closing of the credit agreement, payment of an exit fee amount equal to 10% of the amount of any prepayments. As defined by the agreement, based upon the CDMO segment financial results, OrbiMed has the option to require the Company to prepay a portion of the loan balance based upon an Excess Cash Flow calculation. No payments under this option shall be subject to the buy-out premium. As of September 30, 2017, the Company has paid $22,653 of principal payments on the senior secured loan from the Excess Cash Flow calculation. The credit agreement carries interest at three month LIBOR plus 14.0% with a 1.0% floor. The Company’s obligations under the senior term loan are secured by substantially all of the Company’s assets. The credit agreement contains certain usual and customary affirmative and negative covenants, as well as financial covenants that the Company will need to satisfy on a monthly and quarterly basis. As of September 30, 2017, the Company was in compliance with the covenants. The Company issued to OrbiMed a warrant to purchase 294,928 shares of common stock, with an exercise price of $3.28 per share. The warrant is exercisable through April 10, 2022. The initial fair value of the warrant of $2,861 was recorded as debt issuance costs. Debt issuance costs related to the term loan of $4,579, including the initial warrant fair value of $2,861, are being amortized to interest expense over the five-year term of the loan and netted with the loan principal amount. The unamortized balance of debt issuance costs is $2,457 as of September 30, 2017. As of September 30, 2017, the long-term debt balance is comprised of the following: Principal balance outstanding $ 27,347 Unamortized deferred issuance costs (2,457 ) Total $ 24,890 The Company has estimated that no amount of the Excess Cash Flow payments will become payable within one year of September 30, 2017. The full amount of the debt is classified as long term in the accompanying consolidated balance sheet.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	(13) Commitments and Contingencies (a) Licenses The Company is party to an exclusive license with Orion for the development and commercialization of Dexmedetomidine, or Dex, for use in the treatment of pain in humans in any dosage form for transdermal, transmucosal (including sublingual and intranasal), topical, enteral or pulmonary (inhalational) delivery, but specifically excluding delivery vehicles for administration by injection or infusion, worldwide, except for Europe, Turkey and the CIS (currently includes Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine and Uzbekistan), referred to herein as the Territory. The Company is required to pay Orion lump sum payments of up to €20,500 ($24,215 as of September 30, 2017) on the achievement of certain developmental and commercial milestones, as well as a royalty on net sales during the term, which varies from 10% to 20% depending on annual sales levels. Through September 30, 2017, no such milestones have been achieved. The Company is also party to an exclusive license agreement with Orion for the development and commercialization of Fadolmidine, or Fado, for use as a human therapeutic, in any dosage form in the Territory. The Company is required to pay Orion lump sum payments of up to €12,200 ($14,411 as of September 30, 2017) on achievement of certain developmental and commercial milestones, as well as a royalty on net sales during the term, which varies from 10% to 15% depending on annual sales levels. Through September 30, 2017, no such milestones have been achieved. The Company is party to a license agreement with Cornell University for the exclusive license of the NMB Related Compounds. Under the terms of the agreement, the Company will pay Cornell an initial upfront fee and Cornell is also entitled to receive additional milestone payments, annual license maintenance fees as well as royalties. See Note 5 for further information regarding these payment obligations. (b) Contingent Consideration for the Gainesville Transaction Pursuant to the purchase and sale agreement governing the Gainesville Transaction, the Company agreed to pay to Alkermes up to an additional $125.0 million in milestone payments including $45 million upon regulatory approval, as well as net sales milestones related to injectable meloxicam and royalties on future product sales of injectable meloxicam between 10% and 12% (subject to a 30% reduction when no longer covered by patent). The Company is party to a Development, Manufacturing and Supply Agreement, or Supply Agreement, with Alkermes (through a subsidiary of Alkermes), pursuant to which Alkermes will (i) provide clinical and commercial bulk supplies of injectable meloxicam formulation and (ii) provide development services with respect to the Chemistry, Manufacturing and Controls section of an NDA for injectable meloxicam. Pursuant to the Supply Agreement, Alkermes will supply the Company with such quantities of bulk injectable meloxicam formulation as shall be reasonably required for the completion of clinical trials of injectable meloxicam. During the term of the Supply Agreement, the Company will purchase its clinical and commercial supplies of bulk injectable meloxicam formulation exclusively from Alkermes, subject to certain exceptions, for a period of time. (c) Litigation The Company is involved, from time to time, in various claims and legal proceedings arising in the ordinary course of its business. Except as disclosed below, the Company is not currently a party to any such claims or proceedings that, if decided adversely to it, would either individually or in the aggregate have a material adverse effect on its business, financial condition or results of operations. As part of the Gainesville Transaction, the Company acquired the rights to Zohydro ER®, which the Company licenses to its commercial partner, Pernix Therapeutics Holdings, Inc., or Pernix, in the United States, and which is subject to ongoing intellectual property litigation and proceedings. Zohydro ER® has been subject to six paragraph IV certifications, two of which were filed in 2014 by Actavis plc, or Actavis, and Alvogen Pine Brook, Inc., or Alvogen, regarding the filing of Abbreviated NDAs, or ANDAs, with the FDA for a generic version of Zohydro ER®, one of which was filed in April 2015 by Actavis regarding the filing of a supplemental ANDA, or sANDA, and another three of which were filed in November 2015 and October 2016 by Actavis, and in December 2015 by Alvogen regarding one of the Company’s recently issued patents relating to a formulation of Zohydro ER®. These certification notices allege that three U.S. patents listed in the FDA’s Orange Book for Zohydro ER®, with an expiration date of November 2019 and September 2034, will not be infringed by Actavis’ or Alvogen’s proposed products, are invalid and/or are unenforceable. In 2014, Daravita Limited (a subsidiary of Alkermes and the Company’s predecessor in interest) filed suit against each of Actavis and Alvogen in the U.S. District Court for the District of Delaware based on the ANDAs, and in 2015, the Company filed suit against Actavis in the U.S. District Court for the District of Delaware based on the sANDA. In September 2016, Recro Gainesville LLC entered into a settlement agreement with Alvogen pursuant to which the case against Alvogen was dismissed. In February 2017, the District Court in the Actavis case ruled in Recro Gainesville LLC’s favor and enjoined Actavis from selling the proposed generic version of Zohydro ER®. Actavis has appealed this decision to the U.S. Court of Appeals for the Federal Circuit. In October 2017, Recro Gainesville LLC filed suit against Actavis in the U.S. District Court for the District of Delaware based upon another recently issued patent relating to a formulation of Zohydro ER®. Under Recro Gainesville LLC’s license agreement with Pernix, Recro Gainesville LLC has the right to control the enforcement of its patents and related proceedings involving Zohydro ER® and any prospective generic entrant, and Pernix has the obligation to reimburse Recro Gainesville LLC for all reasonable costs of such actions. In addition, in April 2015, the U.S. Patent and Trademark Office, or the USPTO, declared an interference between one of the Company’s patent applications relating to a dosage form of Zohydro ER® and two Purdue Pharma, LP, or Purdue, applications. In April 2016, the USPTO found Recro Gainesville LLC’s claims and the Purdue claims involved in the interference to be invalid. In June 2016, Purdue appealed this decision to the U.S. Court of Appeals for the Federal Circuit and in June 2017, the U.S. Court of Appeals for the Federal Circuit affirmed the decision of the USPTO in Recro Gainesville’s favor and dismissed Purdue’s appeal. (d) Leases On January 1, 2017, the Company entered into a six-year lease for its Malvern, Pennsylvania facility that expires on December 31, 2022. In February 2017, the Company also entered into a three-year lease for office space in Dublin, Ireland that expires April 2020. The Company is also a party to operating leases for office equipment and storage. Rent expense includes rent as well as additional operating and tenant improvement expenses. As of September 30, 2017, future minimum lease payments excluding operating expenses and tenant improvements for the leases, are as follows: Lease payments 2017 $ 151 2018 566 2019 502 2020 405 2021 362 2022 373 Total $ 2,359 (e) Purchase Commitments As of September 30, 2017, the Company had outstanding non-cancelable and cancelable purchase commitments in the amount of $22,338 related to inventory, capital expenditures and other goods and services, including pre-commercial/manufacturing scale-up and clinical activities. (f) Certain Compensation and Employment Agreements The Company has entered into employment agreements with certain of its named executive officers. As of September 30, 2017, these employment agreements provided for, among other things, annual base salaries in an aggregate amount of not less than $918, from that date through calendar year 2018.

Capital Structure

Capital Structure	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Capital Structure	(14) Capital Structure (a) Common Stock The Company is authorized to issue 50,000,000 shares of common stock, with a par value of $0.01 per share. On March 12, 2014, the Company completed an initial public offering, or IPO, in which the Company sold 4,312,500 shares of common stock at $8.00 per share, resulting in gross proceeds of $34,500. In connection with the IPO, the Company paid $4,244 in underwriting discounts, commissions and offering costs, resulting in net proceeds of $30,256. Also in connection with the IPO, all of the outstanding shares of the Company’s Series A Redeemable Convertible Preferred Stock, including accreted dividends, and Bridge Notes, including accrued interest, were converted into common stock. On July 7, 2015, the Company closed a private placement with certain accredited investors in which the Company sold 1,379,311 shares of common stock at a price of $11.60 per share, for net proceeds of $14,812. The Company paid the placement agents a fee equal to 6.0% of the aggregate gross proceeds from the private placement, plus reimbursement of certain expenses. On August 19, 2016, the Company closed an underwritten public offering in which the company sold 1,986,666 shares of common stock at a price per share of $7.50, for net proceeds of $13,367 after deducting underwriting commissions and offering expenses. On December 16, 2016, the Company closed an underwritten public offering in which the company sold 6,670,000 shares of common stock at a price per share of $6.00, for net proceeds of $36,888 after deducting underwriting commissions and offering expenses. (b) Common Stock Purchase Agreement On February 2, 2015, the Company entered into a Common Stock Purchase Agreement, or the Purchase Agreement, with Aspire Capital Fund, LLC, or Aspire Capital, pursuant to which Aspire Capital was committed to purchase, at the Company’s election, up to an aggregate of $10,000 of shares of the Company’s common stock over the 24-month term of the Purchase Agreement. On the execution of the Purchase Agreement, the Company issued 96,463 shares of common stock to Aspire Capital with a fair value of $285, as consideration for entering in the Purchase Agreement. In addition, the Company incurred $253 of costs in connection with the Purchase Agreement, which, along with the fair value of the common stock, has been recorded as deferred equity costs. During 2016, the Company sold 1,143,940 shares of common stock under the Purchase Agreement for $7,796. The agreement expired in February 2017. (c) Preferred Stock The Company is authorized to issue 10,000,000 shares of preferred stock, with a par value of $0.01 per share. As of September 30, 2017, no preferred stock was issued or outstanding. (d) Warrants As of September 30, 2017, the Company had the following warrants outstanding to purchase shares of the Company’s common stock: Number of Shares Exercise Price per Share Expiration Date 140,000 $ 12.00 March 2019 350,000 $ 19.46 April 2022 294,928 $ 3.28 April 2022 The warrant to purchase 350,000 shares is liability classified since it contains a contingent net cash settlement feature. The warrant to purchase 294,928 shares is liability classified since it contains an anti-dilution provision. The fair value of both warrants will be remeasured through settlement or expiration with changes in fair value recognized as a period charge within the statement of operations. The following table summarizes the fair value and the assumptions used for the Black-Scholes option-pricing model for these liability classified warrants. Date of issuance September 30, 2017 December 31, 2016 Fair value $ 5,331 $ 3,412 $ 3,397 Expected dividend yield — % — % — % Expected volatility 80 % 77 % 85 % Risk-free interest rates 1.73 % 1.92 % 1.93 % Remaining contractual term 7 years 4.50 years 5.25 years

Comprehensive Loss

Comprehensive Loss	9 Months Ended
	Sep. 30, 2017
Comprehensive Income Net Of Tax [Abstract]
Comprehensive Loss	(15) Comprehensive Loss The Company’s comprehensive loss is shown on the Consolidated Statements of Operations and Comprehensive Loss as of September 30, 2017, and is comprised of net unrealized gains and losses on the Company’s available-for-sale securities. The total of comprehensive loss for the three and nine months ended September 30, 2017 was $8,987 and $26,005, respectively. The tax effect for the nine months ended September 30, 2017 of other comprehensive loss was $3.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	(16) Stock-Based Compensation The Company established the 2008 Stock Option Plan, or the 2008 Plan, which allows for the granting of common stock awards, stock appreciation rights, and incentive and nonqualified stock options to purchase shares of the Company’s common stock to designated employees, non-employee directors, and consultants and advisors. As of September 30, 2017, no stock appreciation rights have been issued. Subsequent to adoption, the 2008 Plan was amended to increase the authorized number of shares available for grant to 444,000 shares of common stock. In October 2013, the Company established the 2013 Equity Incentive Plan, or the 2013 Plan, which allows for the grant of stock options, stock appreciation rights and stock awards for a total of 600,000 shares of common stock. In June 2015, the Company’s shareholders approved the Amended and Restated Equity Incentive Plan, or the A&R Plan, which amended and restated the 2013 Plan and increased the aggregate amount of shares available for issuance to 2,000,000. On December 1 st st Stock options are exercisable generally for a period of 10 years from the date of grant and generally vest over four years. As of September 30, 2017, 296,453 shares and 174 shares are available for future grants under the A&R Plan and 2008 Plan, respectively. The weighted average grant-date fair value of the options awarded to employees during the nine months ended September 30, 2017 and 2016 was $5.39 and $5.02, respectively. The fair value of the options was estimated on the date of grant using a Black-Scholes option pricing model with the following assumptions: September 30, 2017 2016 Range of expected option life 6 years 6 years Expected volatility 84.71% 79.95% Risk-free interest rate 1.87-2.17% 1.07-1.91% Expected dividend yield — — The following table summarizes stock option activity during the nine months ended September 30, 2017: Number of shares Weighted average exercise price Weighted average remaining contractual life Balance, December 31, 2016 2,611,929 $ 7.01 Granted 1,003,580 7.50 Exercised (4,256 ) 6.21 Expired/forfeited/cancelled (43,233 ) 8.12 Balance, September 30, 2017 3,568,020 $ 7.14 7.3 years Vested 1,897,174 $ 6.68 5.8 years Vested and expected to vest 3,429,561 $ 7.10 7.2 years Included in the table above are 740,000 options granted outside the plan. The grants were made pursuant to the NASDAQ inducement grant exception in accordance with NASDAQ Listing Rule 5635(c)(4). The following table summarizes restricted stock units activity during the nine months ended September 30, 2017. Number of shares Balance, December 31, 2016 7,750 Granted 369,043 Vested and settled (15,050 ) Expired/forfeited/cancelled (1,750 ) Balance, September 30, 2017 359,993 Expected to vest 359,993 During 2017, the Company granted 91,150 performance-based restricted stock units, or RSUs, which vested based on attaining clinical and operational goals during 2017, as well as 277,893 time-based RSUs, which vest over four years. During September 2017, the performance condition associated with the Company’s outstanding performance-based RSUs was achieved, which resulted in stock-based compensation expense of $656. Due to the timing of the achievement, these RSUs were settled with the issuance of common shares in October 2017, and remain outstanding as of September 30, 2017 in the table above. Included in the 15,050 units of restricted stock vested during the nine months ended September 30, 2017 as well as the 89,400 vested but not yet settled performance-based RSUs are 27,987 shares with a weighted average fair value of $8.92 per share that were withheld for withholding tax purposes upon vesting of such awards from stockholders who elected to net share settle such tax withholding obligation. Stock-based compensation expense for the nine months ended September 30, 2017 and 2016 was $4,265 and $2,799, respectively. As of September 30, 2017, there was $11,086 of unrecognized compensation expense related to unvested options and RSUs that are expected to vest and will be expensed over a weighted average period of 2.8 years. The aggregate intrinsic value represents the total amount by which the fair value of the common stock subject to options exceeds the exercise price of the related options. As of September 30, 2017, the aggregate intrinsic value of the vested and unvested options was $4,927 and $2,632, respectively.

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Segment Reporting	(17) Segment Reporting The Company operates through two business segments: an Acute Care segment and a revenue-generating CDMO segment. The Acute Care segment is primarily focused on developing innovative products for hospital and related settings, and the CDMO segment leverages the Company’s formulation expertise to develop and manufacture pharmaceutical products using the Company’s proprietary delivery technologies for commercial partners who commercialize or plan to commercialize these products. Acute Care has no revenue, and its costs consist primarily of expenses incurred in conducting the Company’s clinical and preclinical studies, acquiring clinical trial materials, regulatory activities, personnel costs and pre-commercialization of meloxicam. CDMO revenue streams are derived from manufacturing, royalty and profit-sharing revenues, as well as CDMO’s research and development services performed for commercial partners. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 3). The Company evaluates performance of its reportable segments based on revenue and operating income (loss). The Company does not allocate interest income, interest expense or income taxes to its operating segments. The following table summarizes segment information as of and for the three and nine months ended September 30, 2017: For the Three Months Ended September 30, For the Nine Months Ended September 30, 2017 2016 2017 2016 Revenues: CDMO $ 17,114 $ 16,951 $ 52,790 $ 51,973 Acute Care — — — — Total $ 17,114 $ 16,951 $ 52,790 $ 51,973 Operating income (loss): CDMO $ 7,781 $ 8,621 $ 18,039 $ 19,899 Acute Care (18,484 ) (12,542 ) (45,475 ) (35,616 ) Total $ (10,703 ) $ (3,921 ) $ (27,436 ) $ (15,717 ) Depreciation and amortization: CDMO $ 1,854 $ 1,890 $ 5,556 $ 5,692 Acute Care 23 1 36 1 Total $ 1,876 $ 1,891 $ 5,592 $ 5,693 Capital expenditures: CDMO $ 1,036 $ 933 $ 3,932 $ 2,014 Acute Care 365 — 654 — Total $ 1,401 $ 933 $ 4,586 $ 2,014 September 30, December 31, 2017 2016 Total assets: CDMO $ 88,524 $ 77,828 Acute Care 80,486 105,169 Total $ 169,010 $ 182,997

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	(18) Related Party Transactions The Company’s President and Chief Executive Officer, or CEO, owns a majority of the stock of Malvern Consulting Group, or MCG, a pharmaceutical incubator and consulting firm. The CEO’s husband, who is also a shareholder of the Company, is a consultant and a shareholder of MCG. In addition, the CEO’s son is the President and a shareholder of MCG. During 2016, certain immediate family members of the CEO were employees of MCG, including the CEO’s brother and sister-in-law. Since formation, the Company entered into various transactions with MCG, as detailed below. However, since becoming a public company, the Company sought to decrease its involvement with MCG, and, as of December 31, 2016, the Company no longer has any involvement or transactions with MCG. During 2016, certain of the Company’s executive officers, its CEO, its Senior Vice President, Development and its Senior Vice President, Regulatory Affairs and Quality Assurance, who is also the CEO's sister, provided minimal consulting services from time to time to MCG. Until December 31, 2016, the Company was a party to a Master Consulting Services Agreement with MCG. Pursuant to the agreement, MCG provided the Company with certain consulting services for a fee based upon hourly rates previously approved by the Company’s Board of Directors. In consideration for such services, the Company recorded $88 and $278 for the three and nine months ended September 30, 2016, respectively. A portion of these amounts were used during 2016 to pay a portion of the respective salaries of MCG employees that, as described above, included immediate family members of the Company’s CEO. Until December 31, 2016, the Company was party to an Office Services Agreement with MCG for the lease of an aggregate of 8,458 square feet of office and lab space located at its Malvern, Pennsylvania facility and the provision of IT services and general office support. Pursuant to the Office Services Agreement, the Company paid MCG $155 in the nine months ended September 30, 2016. The Company terminated this agreement on December 31, 2016 and is now a party to a six-year lease directly with the landlord of the Company’s Malvern, Pennsylvania facility (see Note 13). As of December 31, 2016, the Company terminated the Master Consulting Agreement and the Office Services Agreement and MCG no longer provides any services or has any contracts with the Company. The Company’s Senior Vice President, Regulatory and Quality, who is the CEO’s sister, has held that position since 2014. Effective January 1, 2017, the CEO’s sister-in-law and brother, respectively, terminated their employment with MCG and were hired as the Company’s Director of Human Resources and the Company’s Vice President, Manufacturing. The Company’s board of directors approved these hires consistent with the Company’s related person transaction policy.

Summary of Significant Accoun25

Summary of Significant Accounting Principles (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	(a) Basis of Presentation and Principles of Consolidation The accompanying unaudited consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, for interim financial information and with the instructions of Form 10-Q and Article 10 of Regulation S-X and, therefore, do not include all of the information and notes required by the U.S. GAAP for complete annual financial statements. The Company’s consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. In the opinion of management, the accompanying consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s results for the interim periods. Operating results for the three and nine months ended September 30, 2017 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2017. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December 31, 2016 included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016.
Use of Estimates	(b) Use of Estimates The preparation of financial statements and the notes to the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates.
Cash and Cash Equivalents	(c) Cash and Cash Equivalents Cash and cash equivalents represents cash in banks and highly liquid short-term investments that have maturities of three months or less when acquired to be cash equivalents. These highly liquid short-term investments are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of the changes in interest rates.
Property and Equipment	(d) Property and Equipment Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets, which are as follows: three to ten years for furniture and office equipment; six to ten or more years for manufacturing equipment; two to five years for vehicles; 35 to 40 years for buildings; and the shorter of the lease term or useful life for leasehold improvements. Repairs and maintenance cost are expensed as incurred.
Business Combinations	(e) Business Combinations In accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 805, “Business Combinations,” or ASC 805, the Company allocates the purchase price of acquired companies to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. Valuations are performed to assist in determining the fair values of assets acquired and liabilities assumed, which requires management to make significant estimates and assumptions, in particular with respect to intangible assets. Management makes estimates of fair value based upon assumptions believed to be reasonable. These estimates are based in part on historical experience and information obtained from management of the acquired companies and expectations of future cash flows. Transaction costs and restructuring costs associated with the transaction are expensed as incurred. In-process research and development, or IPR&D, is the value assigned to those projects for which the related products have not received regulatory approval and have no alternative future use. Determining the portion of the purchase price allocated to IPR&D requires the Company to make significant estimates. In a business combination, the Company capitalizes IPR&D as an intangible asset, and for an asset acquisition the Company expenses IPR&D in the Consolidated Statements of Operations and Comprehensive Loss on the acquisition date.
Goodwill and Intangible Assets	(f) Goodwill and Intangible Assets Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill is not amortized, but assessed for impairment on an annual basis or more frequently if impairment indicators exist. The impairment model prescribes a two-step method for determining impairment. The first step compares a reporting unit’s fair value to its carrying amount to identify potential goodwill impairment. If the carrying amount of a reporting unit exceeds the reporting unit’s fair value, the second step of the impairment test must be completed to measure the amount of the reporting unit’s goodwill impairment loss, if any. Step two requires an assignment of the reporting unit’s fair value to the reporting unit’s assets and liabilities to determine the implied fair value of the reporting unit’s goodwill. The implied fair value of the reporting unit’s goodwill is then compared with the carrying amount of the reporting unit’s goodwill to determine the goodwill impairment loss to be recognized, if any. Intangible assets include the Company’s royalties and contract manufacturing relationships intangible asset as well as an IPR&D asset. The royalties and contract manufacturing relationships intangible asset is considered a definite-lived intangible asset and is amortized on a straight-line basis over a useful life of six years. Intangible assets related to IPR&D are considered indefinite-lived intangible assets and are assessed for impairment annually or more frequently if impairment indicators exist. If the associated research and development effort is abandoned, the related assets will be written-off, and the Company will record a noncash impairment loss on its Consolidated Statements of Operations and Comprehensive Loss. For those compounds that reach commercialization, the IPR&D assets will be amortized over their estimated useful lives. The impairment test for indefinite-lived intangible assets is a one-step test, which compares the fair value of the intangible asset to its carrying value. If the carrying value exceeds its fair value, an impairment loss is recognized in an amount equal to the excess. Based on accounting standards, it is required that these assets be assessed at least annually for impairment unless a triggering event occurs between annual assessments, which would then require an assessment in the period which a triggering event occurred. The most recent tests as of November 30, 2016, indicated that goodwill and indefinite-lived intangible assets were not impaired. There were no indicators of impairment as of September 30, 2017.
Revenue Recognition	(g) Revenue Recognition The Company generates revenues from research and development, manufacturing, packaging and related services for multiple pharmaceutical companies through its CDMO segment. The agreements that the Company has with its commercial partners provide for manufacturing revenues, royalties and/or profit sharing components. Manufacturing and other related services revenue is recognized when persuasive evidence of an arrangement exists, shipment has occurred and the title to the product and associated risk of loss has passed to the customer, the sales price is fixed or determinable and collectability is reasonably assured. In addition to manufacturing and packaging revenue, the customer agreements have royalties and/or profit sharing payments, computed on the net product sales of the commercial partner. Royalty and profit sharing revenues are generally recognized under the terms of the applicable license, development and/or supply agreement in the period the products are sold and when collectability is reasonably assured. Revenues related to research and development are generally recognized as the related services or activities are performed, in accordance with the contract terms. To the extent that the agreements specify services are to be performed on a fixed basis, revenues are recognized consistent with the pattern of the work performed. In agreements which specify milestones, the Company recognizes revenue from non-refundable milestone payments when the earnings process is complete and the payment is reasonably assured. Non-refundable milestone payments related to arrangements under which the Company has continuing performance obligations would be deferred and recognized over the period of performance.
Concentration of Credit Risk	(h) Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. The Company manages its cash, cash equivalents and short-term investments based on established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company’s accounts receivable balances are concentrated amongst approximately five customers and if any of these customers’ receivable balances should be deemed uncollectible, it could have a material adverse effect on the Company’s results of operations and financial condition.
Research and Development	(i) Research and Development Research and development costs for the Company’s proprietary products/product candidates are charged to expense as incurred. Research and development expenses consist primarily of funds paid to third parties for the provision of services for pre-commercialization and manufacturing scale-up activities, drug development, clinical trials, statistical analysis and report writing and regulatory filing fees and compliance costs. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expenses relating to these costs. Upfront and milestone payments made to third parties who perform research and development services on the Company’s behalf are expensed as services are rendered. Costs incurred in obtaining product technology licenses are charged to research and development expense as acquired IPR&D if the technology licensed has not reached technological feasibility and has no alternative future use.
Stock-Based Awards	(j) Stock-Based Awards The Company measures employee stock-based awards at grant-date fair value and recognizes employee compensation expense on a straight-line basis over the vesting period of the award. Determining the appropriate fair value of stock options requires the input of subjective assumptions, including the expected life of the option and expected stock price volatility. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and/or management uses different assumptions, stock-based compensation expense could be materially different for future awards. The expected life of stock options was estimated using the “simplified method,” as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. For stock price volatility, the Company uses the historical volatility of our publicly traded stock in order to estimate future stock price trends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. Non-employee stock-based awards are revalued until an award vests and the Company recognizes compensation expense on a straight-line basis over the vesting period of each separated vesting tranche of the award, which is known as the accelerated attribution method. The estimation of the number of stock awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from the Company’s current estimates, such amounts are recognized as an adjustment in the period in which estimates are revised.
Income Taxes	(k) Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized. Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the consolidated financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company does not anticipate significant changes in the amount of unrecognized income tax benefits over the next year.
Net Loss Per Common Share	(l) Net Loss Per Common Share Basic net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted average common shares outstanding during the period. For all periods presented, the outstanding common stock options, warrants and unvested restricted stock units have been excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. For purposes of calculating diluted loss per common share, the denominator includes both the weighted average common shares outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. There are no dilutive common stock equivalents for the three and nine months ended September 30, 2017 The following table sets forth the computation of basic earnings per share and diluted earnings per share: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Basic Earnings Per Share Net loss $ (9,055 ) $ (5,379 ) $ (25,997 ) $ (19,803 ) Weighted average common shares outstanding, basic and diluted 19,058,956 10,780,911 19,053,636 9,862,526 Net loss per share of common stock, basic and diluted $ (0.48 ) $ (0.50 ) $ (1.36 ) $ (2.01 ) The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of September 30, 2017 and 2016, as they would be anti-dilutive: September 30, 2017 2016 Options and restricted stock units outstanding 3,928,013 2,363,794 Warrants 784,928 784,928 Amounts in the table above reflect the common stock equivalents of the noted instruments.
Segment Information	(m) Segment Information The Company determined its reportable segments based on its strategic business units, the commonalities among the products and services within each segment and the manner in which the Company reviews and evaluates operating performance. The Company has identified CDMO and Acute Care as reportable segments. Segment disclosures are included in Note 17. Segment operating profit (loss) is defined as segment revenue less segment operating expenses (segment operating expenses consist of general and administrative expenses, research and development expenses, and the change in valuation of contingent consideration and warrants). The following items are excluded from segment operating profit (loss): interest income and expense, and income tax benefit (expense). Segment assets are those assets and liabilities that are recorded and reported by segment operations. Segment operating capital employed represents segment assets less segment liabilities.
Recent Accounting Pronouncements	(n) Recent Accounting Pronouncements In July 2017, the FASB issued Accounting Standards Update, or ASU, No. 2017-11 “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): Accounting for Certain Financial Instruments with Down Round Features,” In May 2017, the FASB issued ASU No. 2017-09, Stock Compensation - Scope of Modification Accounting In January 2017, the FASB issued ASU No. 2017-04 “Intangibles - Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment,” In August 2016, the FASB issued ASU No. 2016-15 “Classification of Certain Cash Receipts and Cash Payments,” In February 2016, the FASB issued ASU No. 2016-02, “ Leases (Topic 842), In September 2015, the FASB issued ASU No. 2015-16, “ Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments,” ASU 2015-16 addresses In July 2015, the FASB issued ASU No. 2015-11, “ Simplifying the Measurement of Inventory,” In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers,”

Summary of Significant Accoun26

Summary of Significant Accounting Principles (Tables)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Computation of Basic Earnings Per Share and Diluted Earnings Per Share	The following table sets forth the computation of basic earnings per share and diluted earnings per share: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Basic Earnings Per Share Net loss $ (9,055 ) $ (5,379 ) $ (25,997 ) $ (19,803 ) Weighted average common shares outstanding, basic and diluted 19,058,956 10,780,911 19,053,636 9,862,526 Net loss per share of common stock, basic and diluted $ (0.48 ) $ (0.50 ) $ (1.36 ) $ (2.01 )
Schedule of Anti-Dilutive Securities	The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of September 30, 2017 and 2016, as they would be anti-dilutive: September 30, 2017 2016 Options and restricted stock units outstanding 3,928,013 2,363,794 Warrants 784,928 784,928

Fair Value of Financial Instr27

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Classification of Assets and Liabilities Measured at Fair Value on Recurring Basis	The Company has classified assets and liabilities measured at fair value on a recurring basis as follows: Fair value measurements at reporting date using Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) At December 31, 2016: Assets: Money market mutual funds (See Note 7) $ 37,079 $ — $ — U.S. Treasury obligations (See Note 7) 20,517 — — Cash equivalents $ 57,596 $ — $ — Liabilities: Warrants (See Note 14(d)) — — $ 3,397 Contingent consideration (See Note 4) — — 69,574 $ — $ — $ 72,971 At September 30, 2017: Assets: Cash equivalents Money market mutual funds (See Note 7) $ 134 $ — $ — Total cash equivalents $ 134 $ — $ — Short-term investments U.S. Treasury obligations (See Note 7) $ 29,507 $ — $ — Total financial assets $ 29,641 $ — $ — Liabilities: Warrants (See Note 14(d)) — — $ 3,412 Contingent consideration (See Note 4) — — 78,897 $ — $ — $ 82,309
Reconciliation of Contingent Consideration and Warrants Measured at Fair Value on Recurring Basis Using Unobservable Inputs	The reconciliation of the contingent consideration and warrants measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows: Warrants Contingent Consideration Balance at December 31, 2016 $ 3,397 $ 69,574 Additions — — Remeasurement 15 9,323 Total at September 30, 2017 $ 3,412 $ 78,897 Current portion — 30,372 Long-term portion 3,412 48,525

Short-term Investments (Tables)

Short-term Investments (Tables)	9 Months Ended
	Sep. 30, 2017
Investments Debt And Equity Securities [Abstract]
Summary of Available-for-sale Securities	The following is a summary of available-for-sale securities as of September 30, 2017. September 30, 2017 Amortized Gross Unrealized Estimated Description Cost Gain Loss Fair Value Money market mutual funds $ 134 $ — $ — $ 134 U.S. Treasury obligations 29,515 — (8 ) 29,507 Total investments $ 29,649 $ — $ (8 ) $ 29,641

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2017
Inventory Disclosure [Abstract]
Components of Inventory	Inventory is stated at the lower of cost and net realizable value. Included in inventory are raw materials and work-in-process used in the production of commercial products. Cost is determined using the first-in, first-out method. Inventory was as follows as of September 30, 2017 and December 31, 2016: September 30, 2017 December 31, 2016 Raw materials $ 2,584 $ 2,618 Work in process 4,472 5,219 Finished goods 3,529 1,793 10,585 9,630 Provision for inventory obsolescence (694 ) (884 ) $ 9,891 $ 8,746

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2017
Property Plant And Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment consists of the following: September 30, 2017 December 31, 2016 Land $ 3,263 $ 3,263 Building and improvements 15,744 15,613 Furniture, office and computer equipment 4,993 3,811 Vehicles 30 30 Manufacturing equipment 22,602 21,508 Construction in progress 4,191 2,198 50,823 46,423 Less: accumulated depreciation and amortization 12,626 9,123 Property, plant and equipment, net $ 38,197 $ 37,300

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Balance of Intangible Assets	The following represents the balance of the intangible assets at September 30, 2017: Cost Accumulated Amortization Net Intangible Assets Royalties and contract manufacturing relationships: $ 15,500 $ 6,404 $ 9,096 In-process research and development 26,400 — 26,400 Total $ 41,900 $ 6,404 $ 35,496 The following represents the balance of intangible assets at December 31, 2016: Cost Accumulated Amortization Net Intangible Assets Royalties and contract manufacturing relationships: $ 15,500 $ 4,467 $ 11,033 In-process research and development 26,400 — 26,400 Total $ 41,900 $ 4,467 $ 37,433
Schedule of Future Amortization Expense	As of September 30, 2017, future amortization expense is as follows: Amortization October - December 2017 $ 645 2018 2,583 2019 2,583 2020 2,583 2021 702 Total $ 9,096

Accrued Expenses and Other Cu32

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2017
Payables And Accruals [Abstract]
Summary of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following: September 30, December 31, 2017 2016 Clinical trial and related costs $ — $ 2,564 Professional and consulting fees 551 360 Payroll and related costs 4,996 4,547 Property plant and equipment 495 720 Deferred revenue 563 418 Income tax payable — 311 Other 2,545 973 $ 9,150 $ 9,893

Long-Term Debt (Tables)

Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Schedule of Long-Term Debt Balance	As of September 30, 2017, the long-term debt balance is comprised of the following: Principal balance outstanding $ 27,347 Unamortized deferred issuance costs (2,457 ) Total $ 24,890

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments Excluding Operating Expenses and Tenant Improvements	As of September 30, 2017, future minimum lease payments excluding operating expenses and tenant improvements for the leases, are as follows: Lease payments 2017 $ 151 2018 566 2019 502 2020 405 2021 362 2022 373 Total $ 2,359

Capital Structure (Tables)

Capital Structure (Tables)	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Schedule of Warrants Outstanding to Purchase Shares of Common Stock	As of September 30, 2017, the Company had the following warrants outstanding to purchase shares of the Company’s common stock: Number of Shares Exercise Price per Share Expiration Date 140,000 $ 12.00 March 2019 350,000 $ 19.46 April 2022 294,928 $ 3.28 April 2022
Summary of Fair Value and Assumptions Used for Black-Scholes Option-pricing Model for Liability Classified Warrants	The following table summarizes the fair value and the assumptions used for the Black-Scholes option-pricing model for these liability classified warrants. Date of issuance September 30, 2017 December 31, 2016 Fair value $ 5,331 $ 3,412 $ 3,397 Expected dividend yield — % — % — % Expected volatility 80 % 77 % 85 % Risk-free interest rates 1.73 % 1.92 % 1.93 % Remaining contractual term 7 years 4.50 years 5.25 years

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Fair Value of Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model	The fair value of the options was estimated on the date of grant using a Black-Scholes option pricing model with the following assumptions: September 30, 2017 2016 Range of expected option life 6 years 6 years Expected volatility 84.71% 79.95% Risk-free interest rate 1.87-2.17% 1.07-1.91% Expected dividend yield — —
Summary of Stock Option Activity	The following table summarizes stock option activity during the nine months ended September 30, 2017: Number of shares Weighted average exercise price Weighted average remaining contractual life Balance, December 31, 2016 2,611,929 $ 7.01 Granted 1,003,580 7.50 Exercised (4,256 ) 6.21 Expired/forfeited/cancelled (43,233 ) 8.12 Balance, September 30, 2017 3,568,020 $ 7.14 7.3 years Vested 1,897,174 $ 6.68 5.8 years Vested and expected to vest 3,429,561 $ 7.10 7.2 years
Summary of Restricted Stock Units Activity	The following table summarizes restricted stock units activity during the nine months ended September 30, 2017. Number of shares Balance, December 31, 2016 7,750 Granted 369,043 Vested and settled (15,050 ) Expired/forfeited/cancelled (1,750 ) Balance, September 30, 2017 359,993 Expected to vest 359,993

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Summary of Segment Information	The following table summarizes segment information as of and for the three and nine months ended September 30, 2017: For the Three Months Ended September 30, For the Nine Months Ended September 30, 2017 2016 2017 2016 Revenues: CDMO $ 17,114 $ 16,951 $ 52,790 $ 51,973 Acute Care — — — — Total $ 17,114 $ 16,951 $ 52,790 $ 51,973 Operating income (loss): CDMO $ 7,781 $ 8,621 $ 18,039 $ 19,899 Acute Care (18,484 ) (12,542 ) (45,475 ) (35,616 ) Total $ (10,703 ) $ (3,921 ) $ (27,436 ) $ (15,717 ) Depreciation and amortization: CDMO $ 1,854 $ 1,890 $ 5,556 $ 5,692 Acute Care 23 1 36 1 Total $ 1,876 $ 1,891 $ 5,592 $ 5,693 Capital expenditures: CDMO $ 1,036 $ 933 $ 3,932 $ 2,014 Acute Care 365 — 654 — Total $ 1,401 $ 933 $ 4,586 $ 2,014 September 30, December 31, 2017 2016 Total assets: CDMO $ 88,524 $ 77,828 Acute Care 80,486 105,169 Total $ 169,010 $ 182,997

Background - Additional Informa

Background - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2017Segment
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Entity incorporation date	Nov. 15, 2007
Number of operating divisions	2

Development-Stage Risks and L39

Development-Stage Risks and Liquidity - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Business Developments Risks And Uncertainties Liquidity [Abstract]
Accumulated deficit	$ 87,265	$ 61,268

Summary of Significant Accoun40

Summary of Significant Accounting Principles - Additional Information (Detail)	1 Months Ended	3 Months Ended	9 Months Ended
	Nov. 30, 2016USD ($)	Sep. 30, 2017shares	Sep. 30, 2017USD ($)Customershares
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Goodwill impairment	$ 0		$ 0
Indefinite-lived intangible assets impairment	$ 0		$ 0
Dilutive common stock equivalent | shares		0	0
Accounts Receivable [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of customers | Customer			5
Royalties and Contract Manufacturing Relationships [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Definite-lived intangible asset, useful lives			6 years
Furniture and Office Equipment [Member] | Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives			3 years
Furniture and Office Equipment [Member] | Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives			10 years
Manufacturing Equipment [Member] | Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives			6 years
Manufacturing Equipment [Member] | Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment useful life			ten or more years
Vehicles [Member] | Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives			2 years
Vehicles [Member] | Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives			5 years
Buildings [Member] | Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives			35 years
Buildings [Member] | Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives			40 years
Leasehold Improvements [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment useful life			the shorter of the lease term or useful life

Summary of Significant Accoun41

Summary of Significant Accounting Principles - Computation of Basic Earnings Per Share and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Basic Earnings Per Share
Net loss	$ (9,055)	$ (5,379)	$ (25,997)	$ (19,803)
Weighted average common shares outstanding, basic and diluted	19,058,956	10,780,911	19,053,636	9,862,526
Net loss per share of common stock, basic and diluted	$ (0.48)	$ (0.50)	$ (1.36)	$ (2.01)

Summary of Significant Accoun42

Summary of Significant Accounting Principles - Schedule of Anti-Dilutive Securities (Detail) - shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Options [Member] | Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding	3,928,013	2,363,794
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding	784,928	784,928

Acquisition of Gainesville Fa43

Acquisition of Gainesville Facility and Meloxicam - Additional Information (Detail) - Gainesville [Member] $ / shares in Units, $ in Millions	Apr. 10, 2015USD ($)$ / sharesshares
Business Acquisition [Line Items]
Business acquisition upfront payment in cash	$ 50
Working capital adjustment	4
Business acquisition contingent consideration possible milestone payments	$ 125
Maximum future net product sales milestone percentage	30.00%
Minimum [Member]
Business Acquisition [Line Items]
Future net product sales milestone percentage	10.00%
Maximum [Member]
Business Acquisition [Line Items]
Future net product sales milestone percentage	12.00%
Regulatory Approval and Net Sales Milestones [Member]
Business Acquisition [Line Items]
Business acquisition contingent consideration possible milestone payments	$ 45
Seven Year Warrant [Member]
Business Acquisition [Line Items]
Purchase common stock with warrant issue | shares	350,000
Warrant, exercise price per share | $ / shares	$ 19.46

NMB Related License Agreement -

NMB Related License Agreement - Additional Information (Detail) - Cornell University [Member] - Neuromuscular Blocking Agents License Agreement [Member] - USD ($)	1 Months Ended
	Jun. 30, 2017	Sep. 30, 2017
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Acquired IPR&D	$ 766,000
Upfront payment obligation	350,000
Operational liabilities and acquisition-related costs	$ 416,000
Acquired IPR&D charge expected deductible period for income tax purposes	15 years
U.S [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Regulatory approval and commercialization milestones	$ 5,000,000
European [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Regulatory approval and commercialization milestones	$ 3,000,000
Component of Accrued Expenses and Other Current Liabilities and Other Non-current Liabilities [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Operational liabilities and acquisition-related costs		$ 329,000

Fair Value of Financial Instr45

Fair Value of Financial Instruments - Classification of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016	Apr. 10, 2015
Warrants [Member]
Liabilities:
Fair value of liabilities, recurring basis	$ 3,412	$ 3,397	$ 5,331
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets:
Fair value of total financial assets, recurring basis	29,641
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Money Market Mutual Funds [Member]
Assets:
Fair value of total financial assets, recurring basis	134	37,079
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | U.S. Treasury Obligations [Member]
Assets:
Fair value of total financial assets, recurring basis		20,517
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | U.S. Treasury Obligations [Member] | Short-term Investments [Member]
Assets:
Fair value of total financial assets, recurring basis	29,507
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Cash Equivalents [Member]
Assets:
Fair value of total financial assets, recurring basis	134	57,596
Significant Unobservable Inputs (Level 3) [Member]
Liabilities:
Fair value of liabilities, recurring basis	82,309	72,971
Significant Unobservable Inputs (Level 3) [Member] | Warrants [Member]
Liabilities:
Fair value of liabilities, recurring basis	3,412	3,397
Significant Unobservable Inputs (Level 3) [Member] | Contingent Consideration [Member]
Liabilities:
Fair value of liabilities, recurring basis	$ 78,897	$ 69,574

Fair Value of Financial Instr46

Fair Value of Financial Instruments - Reconciliation of Contingent Consideration and Warrants Measured at Fair Value on Recurring Basis Using Unobservable Inputs (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2017USD ($)
Warrants [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Balance at December 31, 2016	$ 3,397
Remeasurement	15
Total at September 30, 2017	3,412
Long-term portion	3,412
Contingent Consideration [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Balance at December 31, 2016	69,574
Remeasurement	9,323
Total at September 30, 2017	78,897
Current portion	30,372
Long-term portion	$ 48,525

Short-term Investments - Summar

Short-term Investments - Summary of Available-for-sale Securities (Detail) $ in Thousands	Sep. 30, 2017USD ($)
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 29,649
Gross Unrealized Loss	(8)
Estimated Fair Value	29,641
Money Market Mutual Funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	134
Estimated Fair Value	134
U.S. Treasury Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	29,515
Gross Unrealized Loss	(8)
Estimated Fair Value	$ 29,507

Short-term Investments - Additi

Short-term Investments - Additional Information (Detail) - Investment	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Minimum [Member]
Schedule of Available-for-sale Securities [Line Items]
Investments maturities period	1 month
Maximum [Member]
Schedule of Available-for-sale Securities [Line Items]
Investments maturities period	4 months
U.S. Treasury Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Number of investments with unrealized losses position, less than 12 months	15
U.S. Treasury Obligations [Member] | Maximum [Member]
Schedule of Available-for-sale Securities [Line Items]
Investments maturities period		3 months
Duration of time, investments in continuous unrealized loss position	6 months

Inventory - Components of Inven

Inventory - Components of Inventory (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 2,584	$ 2,618
Work in process	4,472	5,219
Finished goods	3,529	1,793
Inventory	10,585	9,630
Provision for inventory obsolescence	(694)	(884)
Inventory, net	$ 9,891	$ 8,746

Inventory - Additional Informat

Inventory - Additional Information (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2017USD ($)
Inventory Disclosure [Abstract]
Decrease in provision for inventory obsolescence	$ 190

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 50,823	$ 46,423
Less: accumulated depreciation and amortization	12,626	9,123
Property, plant and equipment, net	38,197	37,300
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	3,263	3,263
Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	15,744	15,613
Furniture, Office & Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	4,993	3,811
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	30	30
Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	22,602	21,508
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 4,191	$ 2,198

Property, Plant and Equipment52

Property, Plant and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Property Plant And Equipment [Abstract]
Depreciation expense	$ 1,231	$ 1,245	$ 3,655	$ 3,756

Intangible Assets - Summary of

Intangible Assets - Summary of Balance of Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Cost, Total	$ 41,900	$ 41,900
Accumulated Amortization	6,404	4,467
Net Intangible Assets, Total	35,496	37,433
Royalties and Contract Manufacturing Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Cost, Definite-lived	15,500	15,500
Accumulated Amortization	6,404	4,467
Net Intangible Assets, Definite-lived	9,096	11,033
In-Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Indefinite-lived	$ 26,400	$ 26,400

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Intangible Assets Net Excluding Goodwill [Abstract]
Amortization expense	$ 646	$ 646	$ 1,937	$ 1,937

Intangible Assets - Summary o55

Intangible Assets - Summary of Future Amortization Expense (Detail) - Royalties and Contract Manufacturing Relationships [Member] - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
October - December 2017	$ 645
2,018	2,583
2,019	2,583
2,020	2,583
2,021	702
Total	$ 9,096	$ 11,033

Accrued Expenses - Summary of A

Accrued Expenses - Summary of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Payables And Accruals [Abstract]
Clinical trial and related costs		$ 2,564
Professional and consulting fees	$ 551	360
Payroll and related costs	4,996	4,547
Property plant and equipment	495	720
Deferred revenue	563	418
Income tax payable		311
Other	2,545	973
Total accrued expenses and other current liabilities	$ 9,150	$ 9,893

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Detail) - USD ($)	Apr. 10, 2015	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Debt Instrument [Line Items]
Principal payments of senior secured loan, excess of cash flow calculation			$ 6,324,000
Unamortized balance of debt issuance costs		$ 2,457,000
Estimated of excess cash flow payments amount payable within one year		$ 0		$ 2,236,000
OrbiMed [Member] | Seven Year Warrant [Member]
Debt Instrument [Line Items]
Purchase common stock with warrant issue		294,928
Warrant, exercise price per share		$ 3.28
Warrants, exercisable date		Apr. 10, 2022
OrbiMed Senior Secured Term Loan [Member]
Debt Instrument [Line Items]
Debt issuance costs related to term loan		$ 4,579,000
Unamortized balance of debt issuance costs		2,457,000
OrbiMed Senior Secured Term Loan [Member] | Warrants [Member]
Debt Instrument [Line Items]
Initial warrant fair value		$ 2,861,000
OrbiMed Senior Secured Term Loan [Member] | Term Loan [Member]
Debt Instrument [Line Items]
Term loan face amount	$ 50,000,000
Term loan maturity term	5 years
Term loan interest rate, Description		Interest at three month LIBOR plus 14.0% with a 1.0% floor
Term loan agreement date	Apr. 10, 2015
Term loan payable date	Apr. 10, 2020
Credit agreement prepayment terms		The Company may make voluntary prepayments in whole or in part, subject to: (i) on or prior to the 36-month anniversary of the closing of the credit agreement, payment of a buy-out premium amount equal to (A) for full prepayments of the unpaid principal amount, $75,000 less all previously prepaid principal amounts and all previously paid interest or (B) for partial prepayments of the unpaid principal amount, 0.5 times the partial prepayment amount less interest payments previously paid in respect to the partial prepayment amount and (ii) after the 36-month anniversary of the closing of the credit agreement, payment of an exit fee amount equal to 10% of the amount of any prepayments.
Credit agreement unpaid principal amount	$ 75,000,000
Exit fee percentage	10.00%
Principal payments of senior secured loan, excess of cash flow calculation		$ 22,653,000
OrbiMed Senior Secured Term Loan [Member] | Term Loan [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Term loan variable interest rate		14.00%
OrbiMed Senior Secured Term Loan [Member] | Term Loan [Member] | Floor [Member]
Debt Instrument [Line Items]
Term loan variable interest rate		1.00%

Long-Term Debt - Schedule of Lo

Long-Term Debt - Schedule of Long-Term Debt Balance (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Principal balance outstanding	$ 27,347
Unamortized deferred issuance costs	(2,457)
Total	$ 24,890	$ 22,152

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Jan. 02, 2017	Feb. 28, 2017	Sep. 30, 2017USD ($)	Sep. 30, 2017EUR (€)	Dec. 31, 2016USD ($)
Purchase Commitment [Member]
Supply Commitment [Line Items]
Purchase commitment non cancelable and cancelable			$ 22,338,000
Dublin [Member]
Supply Commitment [Line Items]
Lease commenced date		Feb. 28, 2017
Lease expiration date		Apr. 16, 2020
Term of contract		3 years
Malvern Consulting Group, Inc. (MCG) [Member] | Pennsylvania [Member]
Supply Commitment [Line Items]
Lease commenced date	Jan. 1, 2017
Lease expiration date	Dec. 31, 2022
Term of contract	6 years		6 years	6 years
Gainesville Transaction [Member]
Supply Commitment [Line Items]
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones			$ 125,000,000
Maximum future net product sales milestone percentage			30.00%	30.00%
Gainesville Transaction [Member] | Regulatory Approval and Net Sales Milestones [Member]
Supply Commitment [Line Items]
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones			$ 45,000,000
Minimum [Member] | Gainesville Transaction [Member]
Supply Commitment [Line Items]
Future net product sales milestone percentage			10.00%	10.00%
Maximum [Member] | Executive Officer [Member]
Supply Commitment [Line Items]
Aggregate annual base salaries of employment agreement			$ 918,000
Maximum [Member] | Gainesville Transaction [Member]
Supply Commitment [Line Items]
Future net product sales milestone percentage			12.00%	12.00%
Dexmedetomidine License Agreement [Member]
Supply Commitment [Line Items]
Contingent milestone payments, maximum			$ 24,215,000	€ 20,500,000
Amount of royalty payments due or payable			$ 0		$ 0
Dexmedetomidine License Agreement [Member] | Minimum [Member]
Supply Commitment [Line Items]
Percentage of royalty payments			10.00%	10.00%
Dexmedetomidine License Agreement [Member] | Maximum [Member]
Supply Commitment [Line Items]
Percentage of royalty payments			20.00%	20.00%
Fadolmidine License Agreement [Member]
Supply Commitment [Line Items]
Amount of royalty payments due or payable			$ 0		$ 0
Additional contingent milestones payment			$ 14,411,000	€ 12,200,000
Fadolmidine License Agreement [Member] | Minimum [Member]
Supply Commitment [Line Items]
Percentage of royalty payments			10.00%	10.00%
Fadolmidine License Agreement [Member] | Maximum [Member]
Supply Commitment [Line Items]
Percentage of royalty payments			15.00%	15.00%

Commitments and Contingencies60

Commitments and Contingencies - Schedule of Future Minimum Lease Payments Excluding Operating Expenses and Tenant Improvements (Detail) $ in Thousands	Sep. 30, 2017USD ($)
Commitments And Contingencies Disclosure [Abstract]
2,017	$ 151
2,018	566
2,019	502
2,020	405
2,021	362
2,022	373
Lease payments, Total	$ 2,359

Capital Structure - Additional

Capital Structure - Additional Information (Detail) - USD ($)	Dec. 16, 2016	Aug. 19, 2016	Jul. 07, 2015	Feb. 02, 2015	Mar. 12, 2014	Sep. 30, 2016	Dec. 31, 2016	Sep. 30, 2017
Schedule Of Capitalization Equity [Line Items]
Common stock, shares authorized to issue							50,000,000	50,000,000
Common stock, par value							$ 0.01	$ 0.01
Aggregate net proceeds from private placement						$ 4,175,000
Net proceeds from sale of common stock						$ 13,367,000
Preferred stock, shares authorized							10,000,000	10,000,000
Preferred stock, par value							$ 0.01	$ 0.01
Preferred stock, shares issued							0	0
Preferred stock, shares outstanding							0	0
Warrants, Exercise Price $19.46, Expiring on April 2022 [Member]
Schedule Of Capitalization Equity [Line Items]
Warrants outstanding to purchase shares, Number of Shares								350,000
Warrants, Exercise Price $19.46, Expiring on April 2022 [Member] | Liability Contingent Net Cash Settlement Feature [Member]
Schedule Of Capitalization Equity [Line Items]
Warrants outstanding to purchase shares, Number of Shares								350,000
Warrants, Exercise Price $3.28, Expiring on April 2022 [Member]
Schedule Of Capitalization Equity [Line Items]
Warrants outstanding to purchase shares, Number of Shares								294,928
Warrants, Exercise Price $3.28, Expiring on April 2022 [Member] | Liability Anti-Dilution Provision [Member]
Schedule Of Capitalization Equity [Line Items]
Warrants outstanding to purchase shares, Number of Shares								294,928
Aspire Capital [Member]
Schedule Of Capitalization Equity [Line Items]
Common stock issuance, shares				96,463			1,143,940
Common stock issuance							$ 7,796,000
Term of purchase agreement				24 months
Stock issued at fair value				$ 285,000
Cost incurred in stock issuance				$ 253,000
Common stock purchase agreement, expiration month and year				2017-02
Maximum [Member] | Aspire Capital [Member]
Schedule Of Capitalization Equity [Line Items]
Common stock issuance				$ 10,000,000
Investor [Member]
Schedule Of Capitalization Equity [Line Items]
Aggregate net proceeds from private placement			$ 14,812,000
Placement agents fee percentage			6.00%
Initial Public Offering (IPO) [Member]
Schedule Of Capitalization Equity [Line Items]
Common stock issuance, shares					4,312,500
Sale of stock, price per share					$ 8
Gross proceeds on sale of common stock in initial public offering					$ 34,500,000
Payments on underwriting discounts, commissions and offering costs					4,244,000
Common stock issuance					$ 30,256,000
Private Placement [Member] | Investor [Member]
Schedule Of Capitalization Equity [Line Items]
Common stock issuance, shares			1,379,311
Common stock issuance price			$ 11.60
Underwritten Public Offering [Member]
Schedule Of Capitalization Equity [Line Items]
Common stock issuance, shares	6,670,000	1,986,666
Common stock issuance price	$ 6	$ 7.50
Net proceeds from sale of common stock	$ 36,888,000	$ 13,367,000

Capital Structure - Schedule of

Capital Structure - Schedule of Warrants Outstanding to Purchase Shares of Common Stock (Detail)	9 Months Ended
	Sep. 30, 2017$ / sharesshares
Warrants, Exercise Price $12.00, Expiring on March 2019 [Member]
Class Of Warrant Or Right [Line Items]
Warrants outstanding to purchase shares, Number of Shares | shares	140,000
Warrants outstanding to purchase shares, Exercise Price per Share | $ / shares	$ 12
Warrants outstanding to purchase shares, Expiration Date	2019-03
Warrants, Exercise Price $19.46, Expiring on April 2022 [Member]
Class Of Warrant Or Right [Line Items]
Warrants outstanding to purchase shares, Number of Shares | shares	350,000
Warrants outstanding to purchase shares, Exercise Price per Share | $ / shares	$ 19.46
Warrants outstanding to purchase shares, Expiration Date	2022-04
Warrants, Exercise Price $3.28, Expiring on April 2022 [Member]
Class Of Warrant Or Right [Line Items]
Warrants outstanding to purchase shares, Number of Shares | shares	294,928
Warrants outstanding to purchase shares, Exercise Price per Share | $ / shares	$ 3.28
Warrants outstanding to purchase shares, Expiration Date	2022-04

Capital Structure - Summary of

Capital Structure - Summary of Fair Value and Assumptions Used for Black-Scholes Option-pricing Model for Liability Classified Warrants (Detail) - Warrants [Member] - USD ($) $ in Thousands	Apr. 10, 2015	Sep. 30, 2017	Dec. 31, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value	$ 5,331	$ 3,412	$ 3,397
Expected volatility	80.00%	77.00%	85.00%
Risk-free interest rates	1.73%	1.92%	1.93%
Remaining contractual term	7 years	4 years 6 months	5 years 3 months

Comprehensive Loss - Additional

Comprehensive Loss - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Comprehensive Income Net Of Tax [Abstract]
Total comprehensive loss	$ 8,987	$ 5,379	$ 26,005	$ 19,803
Tax effect of other comprehensive loss			$ 3

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended			9 Months Ended
	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2015	Oct. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options exercisable period				10 years
Stock options vest period				4 years
Weighted average grant-date fair value of the options awarded to employees				$ 5.39	$ 5.02
Stock-based compensation	$ 656			$ 4,265	$ 2,799
Aggregate intrinsic value of vested options	4,927			4,927
Aggregate intrinsic value of unvested options	2,632			$ 2,632
Stock Options Granted Outside Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options, Granted				740,000
Performance-based RSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock units granted				91,150
Number of restricted stock units vested not yet settled				89,400
Number of restricted stock units withheld for withholding tax				27,987
Number of restricted stock units, weighted average fair value per share of shares withheld for withholding tax				$ 8.92
Time Based Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options vest period				4 years
Number of restricted stock units granted				277,893
Performance-based RSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock units granted				369,043
Number of restricted stock units vested				15,050
Unrecognized compensation expense related to unvested options, expected to vest	$ 11,086			$ 11,086
Unrecognized compensation expense related to unvested options, weighted average period				2 years 9 months 19 days
2008 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock appreciation rights issued in period				0
Additional number of shares authorized for grant	444,000			444,000
Shares available for future grants	174			174
2013 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant							600,000
A&R Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant	3,080,396			3,080,396		2,000,000
Increase in share per "Evergreen" provision		619,181	461,215
Percentage of outstanding common stock		5.00%
Shares available for future grants	296,453			296,453

Stock-Based Compensation - Fair

Stock-Based Compensation - Fair Value of Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model (Detail)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of expected option life	6 years	6 years
Expected volatility	84.71%	79.95%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.87%	1.07%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.17%	1.91%

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Detail)	9 Months Ended
	Sep. 30, 2017$ / sharesshares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of shares, beginning balance | shares	2,611,929
Number of shares, Granted | shares	1,003,580
Number of shares, Exercised | shares	(4,256)
Number of shares, Expired/forfeited/cancelled | shares	(43,233)
Number of shares, ending balance | shares	3,568,020
Number of shares, Vested | shares	1,897,174
Number of shares, Vested and expected to vest | shares	3,429,561
Weighted average exercise price, beginning balance | $ / shares	$ 7.01
Weighted average exercise price, Granted | $ / shares	7.50
Weighted average exercise price, Exercised | $ / shares	6.21
Weighted average exercise price, Expired/forfeited/cancelled | $ / shares	8.12
Weighted average exercise price, ending balance | $ / shares	7.14
Weighted average exercise price, Vested | $ / shares	6.68
Weighted average exercise price, Vested and expected to vest | $ / shares	$ 7.10
Weighted average remaining contractual life	7 years 3 months 19 days
Weighted average remaining contractual life, Vested	5 years 9 months 19 days
Weighted average remaining contractual life, Vested and expected to vest	7 years 2 months 13 days

Stock-Based Compensation - Su68

Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail) - Restricted Stock Units [Member]	9 Months Ended
	Sep. 30, 2017shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, beginning balance	7,750
Number of shares, Granted	369,043
Number of shares, Vested and settled	(15,050)
Number of shares, Expired/forfeited/cancelled	(1,750)
Number of shares, ending balance	359,993
Number of shares, Expected to vest	359,993

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)Segment	Sep. 30, 2016USD ($)
Segment Reporting Information [Line Items]
Number of business segments | Segment			2
Revenue	$ 17,114,000	$ 16,951,000	$ 52,790,000	$ 51,973,000
Acute Care [Member]
Segment Reporting Information [Line Items]
Revenue			$ 0

Segment Reporting - Summary of

Segment Reporting - Summary of Segment Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Segment Reporting Information [Line Items]
Revenues	$ 17,114,000	$ 16,951,000	$ 52,790,000	$ 51,973,000
Operating income (loss)	(10,703,000)	(3,921,000)	(27,436,000)	(15,717,000)
Depreciation and amortization	1,876,000	1,891,000	5,592,000	5,693,000
Capital expenditures	1,401,000	933,000	4,586,000	2,014,000
Total assets	169,010,000		169,010,000		$ 182,997,000
CDMO [Member]
Segment Reporting Information [Line Items]
Revenues	17,114,000	16,951,000	52,790,000	51,973,000
Operating income (loss)	7,781,000	8,621,000	18,039,000	19,899,000
Depreciation and amortization	1,854,000	1,890,000	5,556,000	5,692,000
Capital expenditures	1,036,000	933,000	3,932,000	2,014,000
Total assets	88,524,000		88,524,000		77,828,000
Acute Care [Member]
Segment Reporting Information [Line Items]
Revenues			0
Operating income (loss)	(18,484,000)	(12,542,000)	(45,475,000)	(35,616,000)
Depreciation and amortization	23,000	$ 1,000	36,000	$ 1,000
Capital expenditures	365,000		654,000
Total assets	$ 80,486,000		$ 80,486,000		$ 105,169,000

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - Malvern Consulting Group, Inc. (MCG) [Member] $ in Thousands	Jan. 02, 2017	Sep. 30, 2016USD ($)	Sep. 30, 2017	Sep. 30, 2016USD ($)	Dec. 31, 2016ft²
Related Party Transaction [Line Items]
Related party transaction expenses		$ 88		$ 278
MCG consultants service fee description			MCG provided the Company with certain consulting services for a fee based upon hourly rates
Pennsylvania [Member]
Related Party Transaction [Line Items]
Aggregate area of office and lab space | ft²					8,458
Payment of rental fees				$ 155
Lease directly with the landlord	6 years		6 years